Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2020-10-01 Major Shareholding Noti…
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Becoming a substantial holder 2 pages 42.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001 Section 671B. It details the substantial shareholding of Shimano Ventures Limited in Neurotech International Limited, including voting power, relevant interests, consideration paid, and associates. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is not a financial report, management information, or any other type of report but a regulatory notification about shareholding thresholds being crossed.
2020-10-01 English
Completion of Acquisition 2 pages 71.6KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of an acquisition by Neurotech International Limited, including details about the issuance of shares and options pursuant to a prospectus. It does not contain detailed financial statements or comprehensive financial performance data. The focus is on the acquisition completion and capital issuance, which aligns with updates on company fundraising and capital structure changes. The document length is under 5,000 characters and is primarily an announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-09-29 English
NTI Commences Landmark In Vitro Trials of Cannabis Strains 2 pages 79.9KB
Regulatory Filings Classification · 90% confidence The document is a company announcement dated 23 September 2020 from Neurotech International Limited. It details the commencement of in vitro trials on cannabis strains, describing the scientific and research activities planned and ongoing. The content focuses on research and development updates rather than financial results, regulatory filings, or shareholder information. There is no indication of financial statements, earnings data, board changes, voting results, or capital structure updates. The document is a news release about a scientific trial commencement, which fits best under general regulatory announcements or company updates that do not fit other specific categories. Given the absence of financial or governance details, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements.
2020-09-22 English
Ceasing to be a substantial holder 2 pages 14.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001. It details changes in relevant interests and voting securities of a substantial holder, including dates and nature of changes. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management information, but a regulatory disclosure about shareholding changes.
2020-09-09 English
Neurotech Proceeds to in vitro trials after Positive Results 7 pages 488.5KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Neurotech International Limited about the results of cannabinoid analysis on cannabis samples and plans for subsequent in vitro and clinical trials. It includes extensive scientific data, laboratory testing results, and a certificate of analysis with quantitative cannabinoid profiles. The content focuses on research findings and future research plans rather than financial performance or regulatory compliance. There is no indication that this is an annual or interim financial report, audit report, earnings release, or any other financial filing. It is also not a regulatory announcement, management change, or capital update. The document is a scientific and research update related to the company's product development and clinical research pipeline. Given the nature of the content, it best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit into other specific financial or corporate filing categories.
2020-09-06 English
Completion of Placement 1 page 64.2KB
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated 7 September 2020 from Neurotech International Limited regarding the completion of a tranche of a placement, specifically the issue of 67,750,000 shares. It references previous announcements and shareholder approval but does not contain financial statements or detailed financial analysis. The document length is only 1802 characters, which is quite short and consistent with an announcement rather than a full report. The content focuses on fundraising activity (placement of shares), which aligns with capital raising or financing updates. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2020-09-06 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.